



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: *F. et al.*

Serial No.: 08/866,354

Group Art Unit No.: 1801

Filed: May 30, 1997

Examiner: Unknown

For: Neurotrophic Factor Receptors

Docket No.: A-401B

**INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references that was not provided with the references for Serial No. 08/837,199 for consideration by the Examiner.

Applicants also refer to the information disclosed in prior application Serial No. 08/837,199 filed April 14, 1997. The present application is a continuation-in-part of this prior application under 37 C.F.R. 1.60. The information disclosed in the prior application was submitted in accordance with 37 C.F.R. 1.97.]

Applicants' position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Daniel R. Curry  
Attorney for Applicants  
Registration No.: 32,727  
Phone: (805) 447-8102  
Date: September 10, 1997

Please send all future correspondence to:

U.S. Patent Operations/DRC  
M/S 10-1-B  
AMGEN INC.  
Amgen Center  
1840 DeHavilland Drive  
Thousand Oaks, California 91320-1789

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

September 10, 1997

Date

  
Signature